Nootropic · BDNF+ · Russian Clinical Data

Noopept: 1000x Piracetam & What That Actually Means

📄 11 PubMed citations

Last updated: October 2026

Noopept (GVS-111) is a synthetic dipeptide nootropic developed in Russia. The "1000x more potent than piracetam" claim is real, but misleading. Here's what the evidence actually shows about mechanism, clinical data, dosing, and realistic expectations.

🧪 Buy Noopept at Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items
1000x
More Potent Than Piracetam
By weight, in animal studies (PMID: 12596521)
20mg/day
Dose Used in a Russian Stroke Study
2 months (PMID: 22500312)
BDNF+
Brain-Derived Neurotrophic Factor
Raised in rat hippocampus (PMID: 19240853)

Build your own printable peptide tracker

A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

How Noopept Works

Several mechanisms have been proposed, almost all from Russian animal and cell studies. Beyond glutamate signaling, Noopept has been reported to raise neurotrophic factor expression in rats, a different profile from simple racetams.

⚡
Glutamate Receptor Interaction

Rat studies link Noopept's effects to glutamate receptors. In EEG experiments, an NMDA-receptor blocker reduced or abolished the effects of a single dose, while AMPA receptors were tied to the fading of its EEG effects with repeated dosing (PMID: 21414388). In receptor-binding tests on rat brain tissue, Noopept showed only weak competition at AMPA receptor sites (PMID: 21476267). Glutamate is the main excitatory neurotransmitter in learning and memory, but how these findings translate to cognition in people is not established.

🌱
BDNF & NGF Upregulation

The most-studied feature of Noopept in Russian animal research. In rats, Noopept increased hippocampal mRNA for BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) after a single dose, and the effect persisted over 28 days of treatment (PMID: 19240853); a later rat study also reported higher BDNF expression after chronic dosing (PMID: 21395007). These proteins support neuron survival, growth of new connections, and synaptic plasticity. This is the proposed basis for any longer-term effects; it has not been established in humans.

🩸
Ischemia Models & Blood Rheology

Russian animal research reports neuroprotective effects in several brain-ischemia models and improved blood rheology (PMID: 12596521), plus less tissue damage after experimentally induced thrombosis of cortical blood vessels (PMID: 12962045). Whether Noopept improves cerebral blood flow in people has not been shown.

🛡️
Neuroprotection & Antioxidant

Noopept shows neuroprotective effects in cell models: it reduced oxidative damage and lipid peroxidation in cultured human cortical neurons (PMID: 12711349) and protected cells against beta-amyloid toxicity, an Alzheimer's model (PMID: 25096780). Russian researchers also report it reduces the neurotoxic effects of excess calcium and glutamate (PMID: 12962045). Whether this translates to meaningful protection in healthy humans at standard doses is unclear.

What Russian Clinical Trials Show

Most Noopept clinical data comes from Russian studies. The evidence is real but limited: small populations, limited trial quality by Western standards. Here's an honest summary.

Cognitive Performance Improvement (MCI)
Small Russian studies, e.g. an open-label study in stroke patients, 20mg/day for 2 months (PMID: 22500312)
Some benefit (open-label)
Memory Improvement (Healthy Subjects)
Limited data; most trials in impaired populations
Unproven
BDNF Upregulation (Animal Models)
Consistent rat findings; human relevance unclear
Animal only
Anxiety Reduction
Anxiolytic action reported in Russian experimental research (PMID: 12596521)
Mostly animal data
Western RCT Quality Data
Double-blind placebo-controlled trials in Western journals
Very limited

Noopept Dosing Protocol

There is no published evidence that higher doses work better. The only figures below come from the cited Russian research.

ContextDoseFrequencyNotes
Clinical study dose20mg/dayDaily for 2 monthsThe dose used in the open-label Russian stroke study above (PMID: 22500312). The study abstract does not say how the daily dose was divided.
Tablet strengths5mg and 10mgTablet sizes, not a scheduleThe Russian Noopept tablets under clinical assessment in the early 2000s came in 5 and 10mg strengths (PMID: 12596521).
CyclingOptionalOn/off periodsCommon user practice. Tolerance and cycling are unstudied in humans.
Choline StackOptional alpha-GPCWith NoopeptCommon user practice, anecdotally for headaches. Not studied with Noopept.
💡 SUBLINGUAL NOTE

Many users take Noopept sublingually (holding powder or solution under the tongue before swallowing), expecting faster onset or a lower effective dose. We found no published human study comparing sublingual and oral Noopept, so those benefits are anecdotal. Russian researchers report the drug is active when taken orally (PMID: 12596521).

Key Takeaways

What We Know
  • Rat studies link its effects to glutamate (NMDA/AMPA) receptors; the mechanism is still being worked out
  • Increased hippocampal BDNF/NGF expression in rat studies (PMID: 19240853)
  • Small open-label Russian research reports cognitive improvement in stroke patients with mild cognitive impairment (PMID: 22500312)
  • Reported as well tolerated in short-term Russian clinical use (20mg/day for 2 months) (PMID: 22500312)
  • Developed in Russia in the 1990s as a novel dipeptide drug; still in Phase 2 clinical trials there in the early 2000s (PMID: 12962042)
What We Don't Know
  • Western RCT evidence is very limited: most data from Russia
  • Long-term safety profile in humans is poorly studied
  • Whether BDNF benefits in animals translate to humans at normal doses
  • Optimal cycling protocols for preventing tolerance
  • Genuine benefit for healthy young adults vs impaired populations
⚠️ Disclaimer

Educational content only. Noopept is not FDA-approved. Not medical advice. Consult a healthcare provider before use. The HighPeptides Research Team is not responsible for any health outcomes from use of information on this page.

Research-Grade Peptides

Swiss Chems

Our affiliate source for Noopept powder. Check the product page for current lab-testing documentation before buying.

Browse Swiss Chems Peptides →
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost.

Disclaimer

This page is for educational and informational purposes only. It is not medical advice. Always consult with a qualified healthcare provider before starting any supplement or medication. Key claims are cited inline to PubMed; much of the underlying research comes from small Russian animal and clinical studies. HighPeptides may receive affiliate compensation from linked vendors.

Ebook
The Complete Peptide Protocol Guide

67-page guide: protocols, dosing, sourcing. Everything in one place.

Get the guide: $19 (normally $29) → The Protocol & Stack Handbook ($19) The Protocol & Stack Handbook ($19) All ebooks & guides →
📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.